S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Saudi Arabia is slashing oil supply. It could mean higher gas prices for US drivers
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Greek authorities rescue 91 migrants from river islet on border with Turkey
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
Chuck Todd says he's leaving 'Meet the Press' after a tumultuous near-decade moderating the NBC political panel show
Apple is expected to unveil a sleek, pricey headset. Is it the device VR has been looking for?
Having Trouble in Your Trading? (Ad)
Saudi Arabia to reduce oil output by 1 million barrels per day, while rest of OPEC+ extends previous cuts through 2024
Chuck Todd leaving NBC political panel show 'Meet the Press' and being replaced by Kristen Welker
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Saudi Arabia is slashing oil supply. It could mean higher gas prices for US drivers
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Greek authorities rescue 91 migrants from river islet on border with Turkey
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
Chuck Todd says he's leaving 'Meet the Press' after a tumultuous near-decade moderating the NBC political panel show
Apple is expected to unveil a sleek, pricey headset. Is it the device VR has been looking for?
Having Trouble in Your Trading? (Ad)
Saudi Arabia to reduce oil output by 1 million barrels per day, while rest of OPEC+ extends previous cuts through 2024
Chuck Todd leaving NBC political panel show 'Meet the Press' and being replaced by Kristen Welker
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Saudi Arabia is slashing oil supply. It could mean higher gas prices for US drivers
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Greek authorities rescue 91 migrants from river islet on border with Turkey
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
Chuck Todd says he's leaving 'Meet the Press' after a tumultuous near-decade moderating the NBC political panel show
Apple is expected to unveil a sleek, pricey headset. Is it the device VR has been looking for?
Having Trouble in Your Trading? (Ad)
Saudi Arabia to reduce oil output by 1 million barrels per day, while rest of OPEC+ extends previous cuts through 2024
Chuck Todd leaving NBC political panel show 'Meet the Press' and being replaced by Kristen Welker
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Saudi Arabia is slashing oil supply. It could mean higher gas prices for US drivers
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Greek authorities rescue 91 migrants from river islet on border with Turkey
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
Chuck Todd says he's leaving 'Meet the Press' after a tumultuous near-decade moderating the NBC political panel show
Apple is expected to unveil a sleek, pricey headset. Is it the device VR has been looking for?
Having Trouble in Your Trading? (Ad)
Saudi Arabia to reduce oil output by 1 million barrels per day, while rest of OPEC+ extends previous cuts through 2024
Chuck Todd leaving NBC political panel show 'Meet the Press' and being replaced by Kristen Welker

Novartis (NVS) Stock Forecast, Price & News

$98.91
+1.80 (+1.85%)
(As of 06/2/2023 ET)
Compare
Today's Range
$97.89
$98.93
50-Day Range
$90.19
$104.91
52-Week Range
$74.09
$105.56
Volume
3.74 million shs
Average Volume
1.85 million shs
Market Capitalization
$209.65 billion
P/E Ratio
30.43
Dividend Yield
2.30%
Price Target
$82.25

Novartis MarketRank™ Forecast

Analyst Rating
Hold
2.09 Rating Score
Upside/​Downside
16.8% Downside
$82.25 Price Target
Short Interest
Healthy
0.22% of Float Sold Short
Dividend Strength
Moderate
Based on Four Factors
Sustainability
N/A
News Sentiment
0.16mentions of Novartis in the last 14 days
Based on 17 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
8.25%
From $6.67 to $7.22 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.93 out of 5 stars

Medical Sector

589th out of 980 stocks

Pharmaceutical Preparations Industry

296th out of 485 stocks


NVS stock logo

About Novartis (NYSE:NVS) Stock

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Receive NVS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Novartis and its competitors with MarketBeat's FREE daily newsletter.

NVS Stock News Headlines

20 Best Healthcare Dividend Stocks to Invest in (NVS)
Healthcare, like many other sectors, produces dividends. Learn more about how to invest in healthcare trends and earn dividends along the way with MarketBeat.
The How and Why of Investing in Biotech Stocks (NVS)
One fascinating sector to invest in is the biotech sector which includes companies involved in the research and development of therapeutics and vaccines
“One-Stock Millionaire” IGNORES 99.9% of the Market
During the 2008 financial crisis, millionaire trader Jeff Clark stunned the world when he managed to double his readers’ money 26 TIMES… CNBC caught wind of this and asked Jeff to come on live TV to explain his secret.
Iovance Biotherapeutics Spikes on Melanoma BLA FDA Application (NVS)
Iovance Biotherapeutics Inc. (NASDAQ: IOVA) shares spiked over 20% on its advanced-stage melanoma treatment application to the U.S. Food and Drug Admin
Pharma Giants Novartis, Lilly, Merck, and Novo Outperform Market (NVS)
Big pharma stocks Novartis, Eli Lilly, Merck, and Novo Nordisk are outperforming the market, driven by successful drugs and strong earnings growth.
“One-Stock Millionaire” IGNORES 99.9% of the Market
During the 2008 financial crisis, millionaire trader Jeff Clark stunned the world when he managed to double his readers’ money 26 TIMES… CNBC caught wind of this and asked Jeff to come on live TV to explain his secret.
Sandoz : EMA Accepts MAA For Proposed Biosimilar Denosumab
Brokerages Set Novartis AG (NYSE:NVS) PT at $84.40
See More Headlines

NVS Price History

NVS Company Calendar

Ex-Dividend for 3/20 Dividend
3/09/2023
Dividend Payable
3/20/2023
Last Earnings
4/25/2023
Today
6/04/2023
Next Earnings (Estimated)
7/18/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Employees
101,703
Year Founded
1996

Price Target and Rating

Average Stock Price Forecast
$82.25
High Stock Price Forecast
$90.00
Low Stock Price Forecast
$70.00
Forecasted Upside/Downside
-16.8%
Consensus Rating
Hold
Rating Score (0-4)
2.10
Research Coverage
10 Analysts

Profitability

Net Income
$6.96 billion
Pretax Margin
16.56%

Debt

Sales & Book Value

Annual Sales
$50.55 billion
Cash Flow
$6.30 per share
Book Value
$24.60 per share

Miscellaneous

Outstanding Shares
2,119,600,000
Free Float
2,119,388,000
Market Cap
$209.65 billion
Optionable
Optionable
Beta
0.54

Social Links


Key Executives

  • Vasant Narasimhan
    Chief Executive Officer
  • Steffen Lang
    President-Operations
  • Harry Werner Kirsch
    Chief Financial Officer
  • Shreeram Aradhye
    Chief Medical Officer
  • Klaus Moosmayer
    Chief Ethics, Risk & Compliance Officer













NVS Stock - Frequently Asked Questions

Should I buy or sell Novartis stock right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novartis in the last year. There are currently 2 sell ratings, 5 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" NVS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVS, but not buy additional shares or sell existing shares.
View NVS analyst ratings
or view top-rated stocks.

What is Novartis' stock price forecast for 2023?

10 Wall Street analysts have issued twelve-month price objectives for Novartis' shares. Their NVS share price forecasts range from $70.00 to $90.00. On average, they expect the company's stock price to reach $82.25 in the next year. This suggests that the stock has a possible downside of 16.8%.
View analysts price targets for NVS
or view top-rated stocks among Wall Street analysts.

How have NVS shares performed in 2023?

Novartis' stock was trading at $90.72 at the beginning of 2023. Since then, NVS stock has increased by 9.0% and is now trading at $98.91.
View the best growth stocks for 2023 here
.

When is Novartis' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, July 18th 2023.
View our NVS earnings forecast
.

How were Novartis' earnings last quarter?

Novartis AG (NYSE:NVS) issued its quarterly earnings data on Tuesday, April, 25th. The company reported $1.71 EPS for the quarter, beating the consensus estimate of $1.55 by $0.16. The business earned $12.95 billion during the quarter, compared to analysts' expectations of $12.60 billion. Novartis had a net margin of 13.78% and a trailing twelve-month return on equity of 23.29%. The firm's quarterly revenue was up 3.4% compared to the same quarter last year. During the same period in the prior year, the company earned $1.46 EPS.

How often does Novartis pay dividends? What is the dividend yield for Novartis?

Novartis declared an annual dividend on Thursday, February 2nd. Stockholders of record on Friday, March 10th will be given a dividend of $3.4694 per share on Monday, March 20th. This represents a yield of 2.6%. The ex-dividend date is Thursday, March 9th. This is a positive change from the stock's previous annual dividend of $1.18.
Read our dividend analysis for NVS
.

Is Novartis a good dividend stock?

Novartis (NYSE:NVS) pays an annual dividend of $2.27 per share and currently has a dividend yield of 2.30%. The company has been increasing its dividend for 4 consecutive year(s), indicating that it does not yet have a strong track record of dividend growth. The dividend payout ratio is 69.85%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, NVS will have a dividend payout ratio of 31.44% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for NVS.

What is Vas Narasimhan's approval rating as Novartis' CEO?

938 employees have rated Novartis Chief Executive Officer Vas Narasimhan on Glassdoor.com. Vas Narasimhan has an approval rating of 95% among the company's employees. This puts Vas Narasimhan in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Novartis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Novartis investors own include Johnson & Johnson (JNJ), Pfizer (PFE), AbbVie (ABBV), Intel (INTC), AT&T (T), Walt Disney (DIS), Gilead Sciences (GILD), Cisco Systems (CSCO), Merck & Co., Inc. (MRK) and NVIDIA (NVDA).

What is Novartis' stock symbol?

Novartis trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVS."

Who are Novartis' major shareholders?

Novartis' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Dodge & Cox (0.96%), Envestnet Asset Management Inc. (0.40%), Bank of America Corp DE (0.36%), Franklin Resources Inc. (0.33%), Dimensional Fund Advisors LP (0.29%) and Charles Schwab Investment Management Inc. (0.21%).

How do I buy shares of Novartis?

Shares of NVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Novartis' stock price today?

One share of NVS stock can currently be purchased for approximately $98.91.

How much money does Novartis make?

Novartis (NYSE:NVS) has a market capitalization of $209.65 billion and generates $50.55 billion in revenue each year. The company earns $6.96 billion in net income (profit) each year or $3.25 on an earnings per share basis.

How many employees does Novartis have?

The company employs 101,703 workers across the globe.

Does Novartis have any subsidiaries?
The following companies are subsidiares of Novartis: 1 A Pharma GmbH, Abadia Retuerta S.A, Admune Therapeutics, Advanced Accelerator Applications, Advanced Accelerator Applications, Advanced Accelerator Applications International SA, Advanced Accelerator Applications S.A., Advanced Accelerator Applications S.r.l., Advanced Accelerator Applications USA Inc., Aeropharm GmbH, Alcon, Alcon – Couvreur NV, Amblyotech, Amblyotech Inc., Arctos Medical, Arctos Medical AG, Australia Pty Ltd, Beijing Novartis Pharma Co. Ltd., BioMedical Research Co. Ltd., CELLforCURE, Cadent Therapeutics, Cadent Therapeutics Cambridge, Cellerys, Cellerys AG, CellforCure, Chiron Corporation, Ciba-Geigy Japan Limited, Co. Ltd, CoStim Pharmaceuticals, CoStim Pharmaceuticals Inc., Coalesce Product Development Limited, Corthera, Development Co. Ltd., EBEWE Pharma Ges.m.b.H Nfg. KG, Encore Vision, Endocyte, Endocyte Inc., Eon Labs Inc., Farmanova Saglik Hizmetleri Ltd, Fougera Pharmaceuticals, Fougera Pharmaceuticals Inc, Gyroscope Therapeutics, HEXAL AG, Hexal, IDB Holland BV, Iberica S.L.U., Ilaçlari Sanayi ve Ticaret A.S, JSC Sandoz, Japat AG, Kedalion Therapeutics Inc., Lek Pharmaceuticals d.d., Lek S.A., Manufacturing Pte Ltd , Navigate BioPharma Services Inc, Neutec Pharma Limited, Novartis (Hellas) S.A.C.I., Novartis (Singapore) Pte Ltd, Novartis (Taiwan) Co. Ltd, Novartis (Thailand) Limited, Novartis Argentina S.A., Novartis Australia Pty Ltd, Novartis Austria GmbH, Novartis Biociências S.A., Novartis Biosciences Perú S.A., Novartis Bioventures AG, Novartis Business Services GmbH, Novartis Capital Corporation, Novartis Chile S.A., Novartis Corporation, Novartis Corporation Sdn. Bhd., Novartis Deutschland GmbH, Novartis Ecuador S.A., Novartis Farma S.p.A., Novartis Farma – Produtos Farmacêuticos S.A., Novartis Farmacéutica S.A, Novartis Farmacéutica S.A. de C.V., Novartis Finance Corporation, Novartis Finance S.A., Novartis Finance Services Ltd, Novartis Finland Oy Espoo, Novartis Gene Therapies, Novartis Gene Therapies EU Limited, Novartis Gene Therapies Inc., Novartis Grimsby Limited, Novartis Groupe France S.A., Novartis Healthcare A/S, Novartis Healthcare Philippines Inc., Novartis Healthcare Private Limited, Novartis Holding AG, Novartis Hungary Healthcare Limited Liability Company, Novartis India Limited, Novartis Inflammasome Research, Novartis Integrated Services Limited, Novartis International AG, Novartis International Pharmaceutical Investment AG, Novartis Investment Ltd, Novartis Investments S.à r.l., Novartis Ireland Limited, Novartis Israel Ltd, Novartis Korea Ltd., Novartis Middle East FZE, Novartis Netherlands B.V., Novartis Neva LLC, Novartis New Zealand Ltd, Novartis Norge AS, Novartis Ophthalmics AG, Novartis Optogenetics Research Inc., Novartis Overseas Investments AG, Novartis Pharma (Logistics) Inc., Novartis Pharma (Pakistan) Limited, Novartis Pharma AG, Novartis Pharma B.V. , Novartis Pharma GmbH, Novartis Pharma GmbH, Novartis Pharma K.K., Novartis Pharma LLC, Novartis Pharma Maroc SA, Novartis Pharma NV, Novartis Pharma Produktions GmbH, Novartis Pharma S.A.E., Novartis Pharma S.A.S., Novartis Pharma Schweiz AG, Novartis Pharma Schweizerhalle AG, Novartis Pharma Services AG, Novartis Pharma Services Romania S.R.L., Novartis Pharma Stein AG, Novartis Pharmaceuticals Canada Inc., Novartis Pharmaceuticals Corporation, Novartis Pharmaceuticals Limited, Novartis Pharmaceuticals UK Limited, Novartis Poland Sp. z o.o., Novartis Portugal S.G.P.S. Lda., Novartis Ringaskiddy Limited, Novartis Saglik Gida ve Tarim Ürünleri Sanayi ve Ticaret A.S, Novartis Saudi Ltd., Novartis Securities Investment Ltd, Novartis Services Inc., Novartis Slovakia s.r.o., Novartis South Africa (Pty) Ltd, Novartis Sverige AB, Novartis UK Limited, Novartis US Foundation, Novartis Vaccines and Diagnostics Inc, Novartis Vietnam Company Limited, Novartis de Colombia S.A., Novartis de Venezuela S.A., Novartis s.r.o., Oriel Therapeutics Inc., PT. Novartis Indonesia, Protez Pharmaceuticals, Pte Ltd, Research Inc, Salutas Pharma GmbH, Sandoz A/S, Sandoz AG, Sandoz B.V., Sandoz Canada Inc., Sandoz Egypt Pharma S.A.E., Sandoz Farmacéutica S.A., Sandoz Farmacêutica Lda., Sandoz GmbH, Sandoz Hungary Limited Liability Company, Sandoz Ilaç Sanayi ve Ticaret A.S., Sandoz Inc, Sandoz Industrial Products S.A, Sandoz International GmbH, Sandoz K.K., Sandoz Limited, Sandoz Manufacturing Inc., Sandoz NV, Sandoz Pharma K.K, Sandoz Pharmaceuticals AG, Sandoz Pharmaceuticals d.d., Sandoz Philippines Corporation, Sandoz Polska Sp. z o.o. , Sandoz Private Limited, Sandoz Pty Ltd, Sandoz S.A. de C.V, Sandoz S.A.S., Sandoz S.R.L., Sandoz S.p.A., Sandoz South Africa (Pty) Ltd, Sandoz Ukraine LLC, Sandoz d.o.o. farmaceutska industrija, Sandoz do Brasil Indústria Farmacêutica Ltda, Sandoz s.r.o., Selexys Pharmaceuticals Corporation, Shanghai Novartis Trading Ltd., Société par actions SANDOZ, Spinifex Pharmaceuticals, The Medicines Company, The Medicines Company, Triangle International Reinsurance Limited, Trinity River Insurance Co Ltd, Vedere Bio, Vedere Bio ll, Xiidra, Ziarco, and Ziarco Group Limited.
Read More
How can I contact Novartis?

Novartis' mailing address is LICHTSTRASSE 35, BASEL V8, CH 4056. The official website for the company is www.novartis.com. The company can be reached via phone at (161) 324-1111, via email at investor.relations@novartis.com, or via fax at 41-61-324-7826.

This page (NYSE:NVS) was last updated on 6/4/2023 by MarketBeat.com Staff

My Account -